Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
Parkinson disease Clinical criteria: The treatment must be as adjunctive therapy to a levodopa-decarboxylase inhibitor combination. Treatment criteria: Must be treated by a medical practitioner; OR Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.
“Rotigotine is a non-ergolinic dopamine receptor agonist for the treatment of idiopathic Parkinson's disease and restless legs syndrome (RLS). In vitro binding studies and functional assays indicate a high affinity for the dopaminergic system (D1, D2, D3, D4, D5 receptors), particularly D3 receptors.”
“The clearance of rotigotine after transdermal administration is approximately 10 L/min and its overall elimination half-life is 5 to 7 hours. The pharmacokinetic profile shows a biphasic elimination with an initial half-life of about 2.4 to 3 hours.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Rotigotine is metabolised by CYP2C19, and also weakly inhibits CYP2C19 at high concentrations. Coadministration of omeprazole (inhibitor of CYP2C19), in doses of 40 mg/day, had no effect on the pharmacokinetics and metabolism of rotigotine in healthy volunteers.”